Olaparib

141 interactions 358 cited references

Also sold as: Lynparza Lynparza®

About Olaparib

Olaparib is used alone or in combination with bevacizumab (Avastin) to help maintain the response of certain types of ovarian (female reproductive organs where eggs are formed), fallopian tube (tube that transports eggs released by the ovaries to the uterus), and peritoneal (layer of tissue that lines the abdomen) canc… Read the full Olaparib drug information page →

Medically reviewed by Dr. Brian Staiger, PharmD, BCPS · Updated Aug 9, 2026 · Editorial policy · Data sources

Sources: FDA prescribing information (Structured Product Labeling), the published literature cited in each entry, DDInter 2.0 (a major open-access drug-interaction database), and legacy DrugBank interaction data distributed by the NIH's RxNav service (decommissioned in 2024) — analyzed and reviewed by our pharmacist team. How we build this library →

Most serious with: Dengue Tetravalent Vaccine, Live Bacillus Of Calmette And Guerin Vaccine, Live Measles Virus Vaccine, Live Mifepristone Levoketoconazole Yellow Fever Vaccine

12 Contraindicated 122 Major 7 Moderate

All (141) Contraindicated (12) Major (122) Moderate (7)

Major

Olaparib Crizotinib Xalkori Increased olaparib exposure Details Olaparib Cyclosporine Atopica Increased olaparib exposure Details Olaparib Daridorexant Increased CYP3A4 substrate with NTI exposure Details Olaparib Darunavir Increased olaparib exposure Details Olaparib Delavirdine Rescriptor® Increased olaparib exposure Details Olaparib Diltiazem Cardizem Increased olaparib exposure Details Olaparib Dronedarone Multaq Increased olaparib exposure Details Olaparib Ebola Zaire Vaccine, Live An increased risk of infection by the live vaccine Details Olaparib Efavirenz Decreased olaparib exposure and efficacy Details Olaparib Elinzanetant Lynkuet Increased CYP3A4 substrate with NTI exposure and an increased CYP3A4 substrate with NTI-related adverse reactions Details Olaparib Enzalutamide Xtandi Decreased olaparib exposure and efficacy Details Olaparib Erythromycin Erythrocin Stearate Increased olaparib exposure Details Olaparib Etravirine Intelence Decreased olaparib exposure and efficacy Details Olaparib Fluconazole Diflucan Increased olaparib exposure Details Olaparib Fluvoxamine Increased olaparib exposure Details Olaparib Fosamprenavir Lexiva Increased olaparib exposure Details Olaparib Fosaprepitant Emend Injection Increased olaparib exposure Details Olaparib Fosphenytoin Cerebyx Decreased olaparib exposure and efficacy Details Olaparib Gepotidacin Blujepa Increased CYP3A4 substrate with NTI exposure Details Olaparib Haloperidol Increased haloperidol exposure and an increased risk of haloperidol-related adverse events, including QTc interval prolongation Details Olaparib Idelalisib Zydelig Increased olaparib exposure Details Olaparib Imatinib Gleevec Increased olaparib exposure Details Olaparib Indinavir Increased olaparib exposure Details Olaparib Influenza Virus Vaccine, Live An increased risk of infection by the live vaccine Details Olaparib Itraconazole Sporanox Increased olaparib exposure Details Olaparib Ketoconazole Extina Increased olaparib exposure Details Olaparib Lanreotide Altered exposure to CYP3A4 substrate Details Olaparib Lazertinib Lazcluze Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 substrates with NTI-related adverse reactions Details Olaparib Lemborexant Dayvigo Increased lemborexant exposure and an increased risk of lemborexant-related adverse reactions. Details Olaparib Letermovir Prevymis Increased olaparib exposure Details Olaparib Lomitapide Increased lomitapide exposure Details Olaparib Lonafarnib Zokinvy Increased CYP3A substrate with NTI exposure and an increased risk of CYP3A substrate with NTI-related serious or life-threatening... Details Olaparib Lopinavir Increased olaparib exposure Details Olaparib Lorlatinib Lorbrena Reduced CYP3A substrates exposure and reduced efficacy of CYP3A4 substrates Details Olaparib Lumacaftor Decreased olaparib exposure and efficacy Details Olaparib Mavorixafor Xolremdi Increased CYP3A4 substrate with NTI exposure and an increased risk of CYP3A4 with NTI-related adverse events Details Olaparib Mitotane Lysodren Decreased olaparib exposure and efficacy Details Olaparib Mobocertinib Exkivity Decreased plasma concentrations of the CYP3A substrate, which may result in serious therapeutic failure Details Olaparib Modafinil Provigil Decreased olaparib exposure and efficacy Details Olaparib Nafcillin Decreased olaparib exposure and efficacy Details

Check another drug

Still have questions about this combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

Ask the pharmacist

Educational information only, not medical advice. Always confirm interactions with your pharmacist or prescriber before making any change to your medications.